Thus, this study aimed to determine the relationship between immunohistochemistry of p53, CD44, Ki-67, and HER-2/neu genes and demographic characteristics as well as pathological findings, alongside the state and site of cancer and prognosis of these patients to identify high-risk patients and determine the therapeutic regime. Here, ERBB2 is linked to cancer.